1018 ISS
As of the edition of 20 October 2026, 1018 ISS is a drug: marketed; acts on TLR9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Unknown
- Brand name
- Heplisav B
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Dynavax
- Registered trials
- 4, 0 stopped early
- Disease areas
- Immune system; Infections; Blood and lymph; Cancer; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TLR9 | Toll-like receptor 9 | Q9NR96 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Valneva | Lead sponsor of trials | 2024 to now |